Lilly/Takeda (correction)

Lilly said in April that Takeda would take over U.S. marketing for type 2 diabetes treatment Actos. The firm completed Actos detailing obligations in the U.S. at the end of Q1 but will continue to receive royalties on sales through the end of September, after which it will begin receiving a declining residual royalty. In a July 31 story, "The Pink Sheet" stated the Takeda agreement expired in April (1"The Pink Sheet" July 31, 2006, p. 4). Looking forward Lilly expects SG&A to grow at a lower rate than sales. The story reported the firm expected SG&A to grow at a higher rate than sales...